India to tackle global obesity with cheap fat-loss jabs
India is set to release low-cost generic weight-loss injections following the expiration of key patents, which is expected to make such treatments more accessible globally.
A stronger drug than oral Wigovi has been released... Global competition is intensifying
The global obesity drug market is rapidly shifting from injectable treatments to oral medications, marking a possible disruption to the dominance of Novo Nordisk and Eli Lilly.
What is known about users of weight loss drugs – official medication may cost three thousand euros a year
A report reveals that the majority of weight loss drug users in Finland are likely working and relatively affluent, with significant financial implications for the usage of these medications.
The medications are sometimes too expensive, but one cannot jump to the cheapest option
A medical expert highlights the challenges patients face in affording weight management treatments, emphasizing that not all can opt for the cheapest medications available.
Obesity, a breakthrough in treatments
The Italian Senate hosted the signing of the Erice Manifesto on Obesity, emphasizing a comprehensive approach to obesity as a significant public health issue affecting millions.
The hyped "wonder drug" may not necessarily lose a gram - A doctor explains what it's about
A new report highlights the ineffectiveness of certain obesity treatments, with insights from a leading doctor on the underlying reasons.
Impersonating Mountzaro: Illegal Sale of Obesity Treatment Thrives on SNS
There has been a surge in illegal sales of unauthorized diet drugs impersonating Korean Lilly, particularly through social media, amidst growing interest in obesity treatments.
Novo Nordisk achieves a pyrrhic victory with Wegovy pills
Novo Nordisk's new oral obesity drug Wegovy offers only a minor advantage over Eli Lilly in the ongoing pharmaceutical battle for obesity treatments.
The medicine cabinet for 2026: Ozempic's 'pill', multiple cancer therapies, and news in inflammatory pathologies
The article discusses the anticipated developments of leading drugs in 2026, focusing on GLP-1 agonists, new multi-target compounds, and advancements in treatments for obesity and diabetes, along with their expanding applications in other health conditions.
In light of the rise of anti-obesity treatments in the United States, restaurants reduce their portions
In response to the growing prevalence of anti-obesity treatments in the U.S., restaurants are adapting by offering lighter menus and significantly smaller portions to reduce waste.